These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

887 related articles for article (PubMed ID: 25706092)

  • 1. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
    Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
    JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
    Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
    Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
    J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV
    J Viral Hepat; 2018 Oct; 25(10):1180-1188. PubMed ID: 29660224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
    Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
    Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
    J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
    Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
    Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
    Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
    Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
    Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
    Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
    Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
    Chan HL; Tsang OT; Hui YT; Fung J; Lui GC; Lai CL; Wong GL; Chan KH; But DY; Lai MS; Lao WC; Chan CK; Lam YS; Seto WK; Li C; Yuen MF; Wong VW
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1230-1233. PubMed ID: 27869328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
    Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
    Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
    Flisiak R; Janczewska E; Wawrzynowicz-Syczewska M; Jaroszewicz J; Zarębska-Michaluk D; Nazzal K; Bolewska B; Bialkowska J; Berak H; Fleischer-Stępniewska K; Tomasiewicz K; Karwowska K; Rostkowska K; Piekarska A; Tronina O; Madej G; Garlicki A; Lucejko M; Pisula A; Karpińska E; Kryczka W; Wiercińska-Drapało A; Mozer-Lisewska I; Jabłkowski M; Horban A; Knysz B; Tudrujek M; Halota W; Simon K
    Aliment Pharmacol Ther; 2016 Nov; 44(9):946-956. PubMed ID: 27611776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
    Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
    J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
    Pockros PJ; Reddy KR; Mantry PS; Cohen E; Bennett M; Sulkowski MS; Bernstein DE; Cohen DE; Shulman NS; Wang D; Khatri A; Abunimeh M; Podsadecki T; Lawitz E
    Gastroenterology; 2016 Jun; 150(7):1590-1598. PubMed ID: 26976799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    Welzel TM; Hinrichsen H; Sarrazin C; Buggisch P; Baumgarten A; Christensen S; Berg T; Mauss S; Teuber G; Stein K; Deterding K; van Bömmel F; Heyne R; John C; Zimmermann T; Lutz T; Schott E; Hettinger J; Kleine H; König B; Hüppe D; Wedemeyer H
    J Viral Hepat; 2017 Oct; 24(10):840-849. PubMed ID: 28342229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
    Poordad F; Nelson DR; Feld JJ; Fried MW; Wedemeyer H; Larsen L; Cohen DE; Cohen E; Mobashery N; Tatsch F; Foster GR
    J Hepatol; 2017 Oct; 67(4):700-707. PubMed ID: 28645740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
    Pineda JA; Rivero-Juárez A; de Los Santos I; Collado A; Merino D; Morano-Amado LE; Ríos MJ; Pérez-Pérez M; Téllez F; Palacios R; Pérez AB; Mancebo M; Rivero A; Macías J
    HIV Clin Trials; 2018 Feb; 19(1):23-30. PubMed ID: 29447085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
    Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
    Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.